The perceived effects of cannabis products in the management of seizures in CDKL5 Deficiency Disorder

[1]  H. Leonard,et al.  Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 Deficiency Disorder , 2020, Epilepsy Research.

[2]  A. Fattal-Valevski,et al.  Cannabidiol-enriched oil in children and adults with treatment-resistant epilepsy-does tolerance exist? , 2020, Brain and Development.

[3]  E. Pestana-Knight,et al.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. , 2019, Pediatric neurology.

[4]  Laurie E. Seltzer,et al.  Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results , 2019, Epilepsy Research.

[5]  A. Bergin,et al.  Cannabis for refractory epilepsy in children: A review focusing on CDKL5 Deficiency Disorder , 2019, Epilepsy Research.

[6]  K. Sekar,et al.  Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects , 2019, F1000Research.

[7]  O. Devinsky,et al.  Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study , 2019, Epilepsia.

[8]  Benjamin J. Whalley,et al.  Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models , 2018, Epilepsia.

[9]  O. Devinsky,et al.  Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial , 2018, Epilepsia.

[10]  D. Coyle,et al.  Cannabis‐based products for pediatric epilepsy: A systematic review , 2018, Epilepsia.

[11]  M. Cilio,et al.  Long-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US , 2018, CNS Drugs.

[12]  H. Leonard,et al.  Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder , 2018, Epilepsy Research.

[13]  J. Szaflarski,et al.  Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study , 2018, Epilepsy & Behavior.

[14]  Anup D. Patel,et al.  Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes , 2018, Epilepsy & Behavior.

[15]  Anup D. Patel,et al.  Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results , 2018, Epilepsia.

[16]  N. Lintzeris,et al.  Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community , 2018, Scientific Reports.

[17]  Anup D. Patel,et al.  Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome , 2018, The New England journal of medicine.

[18]  Eric Marsh,et al.  Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial , 2018, The Lancet.

[19]  E. Perucca.  Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? , 2017, Journal of epilepsy research.

[20]  S. Cobb,et al.  CDKL5 variants , 2017, Neurology: Genetics.

[21]  D. Friedman,et al.  Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open‐label clinical study with cannabidiol , 2017, Epilepsia.

[22]  A. Bergin,et al.  Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: Experience of >100 patients , 2017, Epilepsia.

[23]  M. Phillips,et al.  Cannabinoids in Pediatrics. , 2017, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[24]  I. Scheffer,et al.  Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome , 2017, The New England journal of medicine.

[25]  J. Kehne,et al.  Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP) , 2017, Neurochemical Research.

[26]  Benjamin J. Whalley,et al.  Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection , 2017, Epilepsy & Behavior.

[27]  J. Szaflarski,et al.  Social correlates of health status, quality of life, and mood states in patients treated with cannabidiol for epilepsy , 2017, Epilepsy & Behavior.

[28]  J. Christodoulou,et al.  Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder , 2016, Neurology.

[29]  Anup D. Patel,et al.  Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial , 2016, The Lancet Neurology.

[30]  P. Striano,et al.  Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[31]  E. Thiele,et al.  Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy , 2015, Epilepsia.

[32]  C. You,et al.  High dosage of cannabidiol (CBD) alleviates pentylenetetrazole-induced epilepsy in rats by exerting an anticonvulsive effect. , 2015, International journal of clinical and experimental medicine.

[33]  K. Knupp,et al.  Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy , 2015, Epilepsy & Behavior.

[34]  J. Christodoulou,et al.  There is variability in the attainment of developmental milestones in the CDKL5 disorder , 2015, Journal of Neurodevelopmental Disorders.

[35]  E. Maa,et al.  The case for medical marijuana in epilepsy , 2014, Epilepsia.

[36]  Meredith Wilson,et al.  The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy , 2012, European Journal of Human Genetics.

[37]  F. Gilliam,et al.  Adverse effects of antiepileptic drugs , 2012, The Lancet Neurology.

[38]  J. Cramer,et al.  Adverse effects of antiepileptic drugs: a brief overview of important issues , 2010, Expert review of neurotherapeutics.

[39]  J. Gécz,et al.  Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. , 2004, American journal of human genetics.

[40]  J. Olney,et al.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. McPartland,et al.  Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? , 2001 .

[42]  R. Mechoulam,et al.  Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. , 1982, European journal of pharmacology.

[43]  C. R. Craig,et al.  Effects of marihuana cannabinoids on seizure activity in cobalt-epileptic rats , 1982, Pharmacology Biochemistry and Behavior.

[44]  D. Jackson,et al.  Interaction of Δ9‐tetrahydrocannabinol and cannabidiol with phenobarbitone in protecting mice from electrically induced convulsions , 1975, The Journal of pharmacy and pharmacology.